 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

---
- 'Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company
  advancing a pipeline of proprietary small molecule drugs that address inflammatory,
  cancer and liver diseases, today announced it has enrolled the first patient in
  a Phase IIb study of its drug candidate Namodenoson...'


Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

---
- 'PETACH TIKVA, Israel, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
  (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline
  of proprietary small molecule drugs that address inflammatory, cancer and liver
  diseases, today announced the agreement by an healthcare-...'


Can-Fite Announces Exercise of Warrants for Cash Proceeds of $10 Million

---
- Cancer Immunotherapy Gets Boost from Newly Engineered Nanoparticles Cancer Immunotherapy
  Gets Boost from Newly Engineered Nanoparticles FN Media Group Presents USA News
  Group News Commentary PR Newswire LOS ANGELES, June 25, 2020 LOS ANGELES, June 25,
  2020 /PRNewswire/ --USA News Group In a major ...


Cancer Immunotherapy Gets Boost from Newly Engineered Nanoparticles

---
- 'Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company
  advancing a pipeline of proprietary small molecule drugs that address inflammatory,
  cancer and liver diseases, today announced it has successfully concluded a meeting
  with the Scientific Advice Working Party (SAWP) of...'


Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer

---
- 'PETACH TIKVA, Israel, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
  (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline
  of proprietary small molecule drugs that address cancer, liver and inflammatory
  diseases, today announced the pricing of a public offering ...'


Can-Fite BioPharma Announces Pricing of $5 Million Public Offering

---
- 'Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company
  advancing a pipeline of proprietary small molecule drugs that address cancer, liver
  and inflammatory diseases, today announced pre-clinical data generated at the Hadassah
  Medical Center by Dr. Rifaat Safadis lab ...'


New Data From Hadassah Medical Center Lab Show Can-Fites Namodenoson Induces Weight Loss

---
- 'Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with
  a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory
  diseases, announced today that data from its recently completed Phase II trial in
  patients with hepatocellular cancer (HCC), ...'


Findings from Can-Fites Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session

---
- 'PETACH TIKVA, Israel, May 20, 2019 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
  (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline
  of proprietary small molecule drugs that address cancer, liver and inflammatory
  diseases, today announced that it has entered into a ...'


Can-Fite BioPharma Announces $6 Million Registered Direct Offering

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

Watchers	13,394
52-Wk Low	$1.52
52-Wk High	$9.00

Market Cap	$10.57M
Volume (M)	39,952.00
52-Wk High	$9.00
52-Wk Low	$1.52

CANF Can-Fite BioPharma Ltd.

About

Feed

News

Sentiment

Fundamentals